2017 Immuno-Oncology Symposium

Alain Patrick Algazi, MD, Univesrity of California, San Francisco, Medical Center- Mt. Zion, presenting Abstract #78, "Immune monitoring outcomes of patients with stage III/IV melanoma treated with a combination of pembrolizumab and intratumoral plasmid interleukin 12 (pIL-12)"

Orlando, FL - 2017 Clinical Immuno-Oncology Symposium - Alain Patrick Algazi, MD, Univesrity of California, San Francisco, Medical Center- Mt. Zion, presenting Abstract #78, "Immune monitoring outcomes of patients with stage III/IV melanoma treated with a combination of pembrolizumab and intratumoral plasmid interleukin 12 (pIL-12)," during General Session 3 at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium here today, Thursday, February 23, 2017. The conference, which is a collaboration between the American Society of Clinical Oncology and Society for Immunotherapy of Cancer, is focused on clinical and translational research in immuno-oncology and the implications for clinical care. Photo by © ASCO/Luke Franke 2017